What is the tesamorelin dosage?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds Tesamorelin and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
The current US labels give 1.28 mg once daily (Egrifta WR, 0.16 mL of the mixed solution) or 1.4 mg once daily (Egrifta SV) under the skin for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and the original label gave 2 mg once a day.123
The guide's example
2 mg of Tesamorelin from a 10 mg vial mixed with 2 mL is 40 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water | 3 mL of water |
|---|---|---|---|
| 5 mg5% set up10 | 5 mg/mL: 1 mg is 20 units, 2 mg is 40 units | 2.5 mg/mL: 1 mg is 40 units, 2 mg is 80 units | 1.667 mg/mL: 1 mg is 60 units, 2 mg is over 1 mL |
| 10 mg65% set up10 | 10 mg/mL: 1 mg is 10 units, 2 mg is 20 units | 5 mg/mL: 1 mg is 20 units, 2 mg is 40 units | 3.333 mg/mL: 1 mg is 30 units, 2 mg is 60 units |
| 20 mg26% set up10 | 20 mg/mL: 1 mg is 5 units, 2 mg is 10 units | 10 mg/mL: 1 mg is 10 units, 2 mg is 20 units | 6.667 mg/mL: 1 mg is 15 units, 2 mg is 30 units |
Most often logged by Milligram users: 2 mg, 38% logged.10
Mixing a 10 mg vial and reading units
Of the people who logged tesamorelin, 65% set up a 10 mg vial, 26% a 20 mg vial and 5% a 5 mg vial.10 No label covers the vial strengths people set up, so the mL and unit figures in the table are arithmetic only.
The mix set up by the largest share of people was 10 mg + 2 mL (28%), then 10 mg + 1 mL (26%).10 The dose and syringe mark logged by the largest share was 2 mg at 20 units (19%), then 1 mg at 10 units (14%) and 1 mg at 20 units (13%).10 By arithmetic, 20 units holds 2 mg only when 10 mg is mixed in 1 mL (10 mg/mL); in the 10 mg in 2 mL mix worked below (5 mg/mL), 2 mg is 40 units.
2 mg of Tesamorelin from a 10 mg vial mixed with 2 mL is 40 units on a U-100 syringe.
28% set up 10 mg + 2 mL10
What the labels say, and the doses people log
The Egrifta WR label gives 1.28 mg once daily for excess abdominal fat in HIV-infected adults with lipodystrophy, injected under the skin of the abdomen with sites rotated, and says it is not indicated for weight loss management.1 One mixed WR vial provides daily doses for 7 consecutive days.1 The Egrifta SV label gives 1.4 mg once daily, which is 0.35 mL of the mixed solution.2 The WR label says systemic exposure from its 1.28 mg dose is similar to that from the 2 mg dose of the earlier 1 mg vial product, and that WR and SV have different doses and are not substitutable.1 Of the people who logged tesamorelin, 38% logged 2 mg and 36% logged 1 mg.10
What each trial gave
Trials in people with HIV gave 2 mg daily under the skin, and one 12-week dose-ranging trial of 61 HIV-infected adults also tested 1 or 2 mg against placebo.45 The one other dose comparison in the pack was a 12-week trial of 53 patients with type 2 diabetes given placebo, 1 mg or 2 mg tesamorelin.6
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Falutz 20054 | Placebo or 1 or 2 mg subcutaneously, once daily | 61 | 12 weeks |
| Falutz 20075 | 2 mg daily by subcutaneous injection or placebo | 412 | 26 weeks |
| Falutz 20107 | 2 mg subcutaneously every day or placebo (2:1) for six months; the tesamorelin group then continued or switched to placebo, and the placebo group switched to tesamorelin | 404 | 12 months |
| Stanley 20148 | 2 mg daily subcutaneously or placebo | 50 (28 tesamorelin, 22 placebo) | 6 months |
| Clemmons 20176 | Placebo, 1 mg or 2 mg | 53 with type 2 diabetes | 12 weeks |
| Stanley 20199 | 2 mg once daily or placebo, then 2 mg daily open-label | 61 with HIV and non-alcoholic fatty liver disease (30 tesamorelin, 30 placebo) | 12 months, then 6 months |
The pack holds no human dosing trial in healthy adults for body composition. The trial reports in the pack give each arm one dose and describe no starting dose or stepping up; full-text arm details are not in the pack.4
How vials are stored
The Egrifta WR label stores the unmixed 11.6 mg vial at 20 to 25 degrees C in its original box to protect from light, with excursions allowed to 15 to 30 degrees C.1 It stores the mixed vial at 20 to 25 degrees C, discards unused solution 7 days after mixing and says not to freeze it.1 The Egrifta SV label stores its 2 mg vial at 20 to 25 degrees C and says to use the mixed vial right away.2 The original label stored unmixed vials in a refrigerator at 2 to 8 degrees C.3 No label or trial covers storage of a mixed vial at the strengths people set up.
- Tesamorelin calculatorMix and units for other vials.
- Mixing peptidesThe steps for mixing a vial.
- HGH dosage in IUGrowth hormone doses in IU.
- CJC-1295 and ipamorelin dosageA GH-releasing peptide pair.
- How much ipamorelin per dayIpamorelin amounts.
- TesamorelinHalf-life, studies and status.
- Growth hormone peptidesThe compound group.
Frequently asked questions
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- Theratechnologies Inc. via DailyMed (US National Library of Medicine). EGRIFTA WR (tesamorelin) for injection, prescribing information. 2026. dailymed.nlm.nih.gov
- Theratechnologies Inc. via DailyMed (US National Library of Medicine). EGRIFTA SV (tesamorelin) for injection, prescribing information. 2026. dailymed.nlm.nih.gov
- US Food and Drug Administration. EGRIFTA (tesamorelin for injection) prescribing information, NDA 022505, revised 11/2010. 2010. accessdata.fda.gov
- AIDS (PubMed abstract). A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. 2005. pubmed.ncbi.nlm.nih.gov
- New England Journal of Medicine (PubMed abstract). Metabolic effects of a growth hormone-releasing factor in patients with HIV. 2007. pubmed.ncbi.nlm.nih.gov
- PLoS One (PubMed abstract). Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: a randomized, placebo-controlled trial. 2017. pubmed.ncbi.nlm.nih.gov
- J Acquir Immune Defic Syndr (PubMed abstract). Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. 2010. pubmed.ncbi.nlm.nih.gov
- JAMA (PubMed abstract). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. 2014. pubmed.ncbi.nlm.nih.gov
- Lancet HIV (PubMed abstract). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. 2019. pubmed.ncbi.nlm.nih.gov
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted